Plasma protein affinity tags

Details Plasma protein affinity tags Plasma protein affinity tags

2011-03-01

2011-03-01

Gupta, Anish (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S003100, C514S012200, C514S013800, C514S014800, C514S015800

Reexamination Certificate

active

07897560

ABSTRACT:
Method for increasing half-life of therapeutic agents in plasma and novel polypeptide derivatives.

REFERENCES:
patent: 2004/0001827 (2004-01-01), Dennis
patent: 90/11296 (1990-10-01), None
patent: 98/08872 (1997-09-01), None
patent: 99/43341 (1999-02-01), None
patent: 99/43361 (1999-02-01), None
patent: 99/43705 (1999-02-01), None
patent: 99/43707 (1999-02-01), None
patent: 01/04156 (2000-07-01), None
patent: 01/51071 (2001-01-01), None
patent: 02/058725 (2002-01-01), None
patent: WO 02/46227 (2002-06-01), None
patent: 03/002136 (2003-01-01), None
patent: 03/087139 (2003-03-01), None
patent: 2004/074315 (2004-02-01), None
Ngo JT, Marks J, Karplus M. “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox”, The Protein Folding Problems and Tertiary Structure Prediction, K Merc, Jr. and S. Le Grand, Editors, Birkhauser Boston, 1994.
Bradley CM, Barrick D. “Limits of Cooperativity in a Structurally Modular Protein: Response of the Notch ANkyrin Domain to Analogous Alanine Substitutions in Each Repeat”, Journal of Molecular Biology, 2002, 324: 373-386.
Rudinger J, “Characteristics of amino acids as components of a peptide hormone sequence,” from Peptide Hormones, J.A. Parsons, MA, BM, B.Ch., University Park Press, Jun. 1976.
“Designing Custom Peptides” from SIGMA Genosys, pp. 1-2. Accessed Dec. 16, 2004.
Berendsen HJC, “A Glimpse of the Holy Grail?”, Science, Oct. 23, 1998, 282: 642-643.
Schinzel R and Drueckes P, “The phosphate recognition site ofEscherichia colimaltodextrin phosphorylase,” Federation of European Biochemical Society, Jul. 1991, 286(1,2): 125-128.
Voet D and Voet JG, Biochemistry, Second Edition, John Wiley & Sons, Inc., 1995, pp. 235-241.
Deacon, C.F. et al., Diabetologia, vol. 41, pp. 271-278 (1998).
Holz, G.G. et al., Curr Med Chem., vol. 10, pp. 2471-2483 (2003).
Knudsen, L.B. et al., J Med Chem., vol. 43, pp. 1664-1669 (2000).
Kurtzhals P. et al., Bio Chem, vol. 312(3), pp. 725-731 (1995).
Sheffield, W.P. et al., Curr Drug Targets Cardiovasc Haema., vol. 1(1), pp. 1-22 (2001).
Chuang VTG et al., Pharmaceutical Strategies Utilizing Recombinant Human Serum Albumin, Pharmaceutical Research, 2002, vol. 19, No. 5, pp. 569-577.
Han H-K, “Targeted Prodrug Design to Optimize Drug Delivery,” AAPS Pharmsci, 2002, 2(1); 1-11.
Inflammatory Bowel Disease from e-Medicine, pp. 1-24, Accessed Sep. 24, 2008.
Kim, J-G et al., “Development and Characterization of a Glucagon-Like Peptide 1-Albumin Conjugate,” Diabetes, 2003, 52: 751-759.
Pico, G., Studia Biophysica, 2000, vol. 136, No. 1, pp. 21-26.
Residue definition from www.dictionary.com, pp. 1-6, Accessed May 5, 2009.
Small Bowel Syndrome from e-Medicine, pp. 1-21, Accessed Sep. 24, 2008.
Zobel, K. et al., Bioorg Med Chem Lett., 2003, vol. 13, pp. 1513-1515.

Affiliated with

Also associated with

Rating

Plasma protein affinity tags does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Plasma protein affinity tags, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Plasma protein affinity tags will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2725711